1. Home
  2. NGNE vs HQ Comparison

NGNE vs HQ Comparison

Compare NGNE & HQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$35.99

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Logo Horizon Quantum Holdings Ltd. Class A Ordinary Shares

HQ

Horizon Quantum Holdings Ltd. Class A Ordinary Shares

N/A

Current Price

$16.45

Market Cap

623.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NGNE
HQ
Founded
2003
2018
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
623.1M
IPO Year
2014
2025

Fundamental Metrics

Financial Performance
Metric
NGNE
HQ
Price
$35.99
$16.45
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$63.57
N/A
AVG Volume (30 Days)
174.1K
283.0K
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
0.93
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.93
$8.29
52 Week High
$43.66
$45.00

Technical Indicators

Market Signals
Indicator
NGNE
HQ
Relative Strength Index (RSI) 53.66 51.75
Support Level $31.83 $9.79
Resistance Level $43.66 $45.00
Average True Range (ATR) 2.07 2.08
MACD 0.05 0.37
Stochastic Oscillator 72.75 83.79

Price Performance

Historical Comparison
NGNE
HQ

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About HQ Horizon Quantum Holdings Ltd. Class A Ordinary Shares

Horizon Quantum Holdings Ltd is building software infrastructure to make quantum computers accessible to commercial enterprises and hardware providers. By bridging the gap between hardware and applications, the company seeks to equip developers, researchers, and enterprises with the quantum software infrastructure needed to solve real-world problems. The company is developing tools that can automatically accelerate code written for conventional computers on quantum computers.

Share on Social Networks: